Hello Heart is an Israeli medtech startup offering a digital program that helps users to understand and improve their heart health. Heart conditions are the number one cost factor for employers. The Hello Heart program is clinically based and targets people with high blood pressure. Now a JAMA study of over 28,000 participants found that 84% of Hello Heart users successfully reduced their blood pressure.
Launched in 2013, the digital therapeutic company’s app helps patients manage their blood pressure, pulse, medications and physical activity using artificial intelligence.
Every participant receives a wireless blood pressure monitor and real-time personalized tips on their smartphone. The solution, says the company, helps participants improve their heart health in a fun and engaging way. Hello Heart delivers real results – enrollment rates are 45% of targeted employees, and 70% of participants at risk reduce their blood pressure using Hello Heart.
“When my partner was diagnosed with a serious disease I found myself in the patient’s seat. I started tracking vital signs, collecting medical records and spending hours online trying to understand it. I realized that as patients, we don’t have tools to understand and improve our health. It’s time to change that,” Maayan Cohen, Hello Heart CEO.
According to a study published in the JAMA Network Open, a peer-reviewed Journal of the American Medical Association, the Hello Heart digital health application for blood pressure management can achieve and maintain lower blood pressure over time, even for those most at risk for heart disease. The results showed that over 84 percent of participants with stage II hypertension achieved a reduction in their systolic blood pressure, which was maintained over three years. This research is the largest multi-year study of the efficacy of a digital therapeutic in controlling hypertension.
Can a digital therapeutic help reduce BP & sustain it over time? Yes, according to our new peer-reviewed research published today in @JAMANetworkOpen, the largest and longest study of its kind.
Read here: https://t.co/bH6m44jQoA
— Hello Heart (@HelloHeartApp) October 15, 2021
“There is a high amount of skepticism and cynicism around hypertension management solutions because for years, there has been no effective solution, and current solutions yield low participant engagement. We’re pleased that the study demonstrated such strong clinical results that are sustained over three years for Hello Heart users,” said Maayan Cohen, CEO of Hello Heart. “It can be very uncomfortable and even scary for companies to subject their findings to a peer review. We have been helping users with their cardiac health for several years and are proud to put our clinical results through a peer-review process that validates what we already know—Hello Heart has strong, sustained clinical impact, at scale.”
This past May, Hello Heart brought in $45 million in a Series C round was led by IVP, to build out its technology
“Hypertension is the most prevalent chronic condition in America, impacting roughly half the U.S. population,” Parsa Saljoughian, partner at IVP, said in a press release.